Details of the Drug

General Information of Drug (ID: DMTY9LU)

Drug Name

Piperazine

Synonyms

Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine

Indication

Disease Entry	ICD 11	Status	REF
Ascariasis	1F62	Approved	[1]
Enterobiasis	1F65	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antinematodal Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

86.14

Logarithm of the Partition Coefficient (xlogp)

-1.5

Rotatable Bond Count (rotbonds)

0

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

2

ADMET Property

Absorption: The drug is rapidly absorbed from the gastrointestinal tract []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Elimination: 50% of drug is excreted from urine in the unchanged form [2]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 580.466 micromolar/kg/day [3]
Water Solubility: The ability of drug to dissolve in water is measured as 260 mg/mL [2]

Chemical Identifiers

Formula: C4H10N2
IUPAC Name: piperazine
Canonical SMILES: C1CNCCN1
InChI: InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2
InChIKey: GLUUGHFHXGJENI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4837
ChEBI ID: CHEBI:28568
CAS Number: 110-85-0
DrugBank ID: DB00592
TTD ID: D01XLM
INTEDE ID: DR1297
ACDINA ID: D00535

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Antagonist	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[6]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[6]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Protein Interaction/Cellular Processes	[6]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Gene/Protein Processing	[6]
Interleukin-2 (IL2)	OTGI4NSA	IL2_HUMAN	Gene/Protein Processing	[7]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Gene/Protein Processing	[6]
Tyrosine 3-monooxygenase (TH)	OT6ZORKP	TY3H_HUMAN	Gene/Protein Processing	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Piperazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Piperazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[8]
Bupropion	DM5PCS7	Major	Decreased metabolism of Piperazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[9]
-----------

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Brushite	E00392	104805	Diluent
Magnesium stearate	E00208	11177	lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Piperazine 100 mg tablet	100 mg	Chewable Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS applied to over 900 drugs
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
5	Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31.
6	Comparing the dopaminergic neurotoxic effects of benzylpiperazine and benzoylpiperazine. Toxicol Mech Methods. 2018 Mar;28(3):177-186. doi: 10.1080/15376516.2017.1376024. Epub 2017 Sep 28.
7	The synthesis and selective IL-2 inhibitory activity of bis piperazine-phenol Mannich adducts. Bioorg Med Chem Lett. 2002 Mar 11;12(5):775-8. doi: 10.1016/s0960-894x(02)00011-2.
8	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
9	Canadian Pharmacists Association.